Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of December 2025. The filing details a specific share repurchase executed on December 19, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing focuses exclusively on share repurchase activity and capital structure updates. It does not contain revenue, profit, cash flow, or margin data.
- Shares Purchased (Dec 19, 2025): 232,912 ordinary shares.
- Price Range: Lowest 1,798.50p; Highest 1,818.00p.
- Volume-Weighted Average Price (VWAP): 1,807.58p.
- Programme Progress: Since September 30, 2025, the Company has purchased 14,554,645 ordinary shares.
- Treasury Shares Held: 240,019,489 ordinary shares.
- Shares in Issue (excluding Treasury): 4,075,425,537 ordinary shares.
- Total Voting Rights: 4,075,425,537.
- Treasury Voting Rights Percentage: 5.89%.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares following the December 19 transaction. The total number of voting rights remains 4,075,425,537, as treasury shares do not carry voting rights. The percentage of voting rights attributable to treasury shares is confirmed at 5.89%.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the "Risk Factors" section of the 2024 Annual Report on Form 20-F and the Q3 Results for 2025. No unusual items or contingencies are disclosed in this specific filing.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since September 30, 2025 (14,554,645 shares).
- Confirm the updated count of treasury shares (240,019,489) and shares in issue (4,075,425,537).
- Review the 2024 Annual Report on Form 20-F and Q3 2025 Results for the full list of risk factors referenced in the cautionary statement.
- Check the remaining authorization or budget for the ongoing buyback programme, as this filing does not specify the total programme size or remaining capacity.